Efficacy and Safety of Biosimilar FYB201 Compared with Ranibizumab in Neovascular Age-Related Macular Degeneration

202167 citationsJournal Articlehybrid Open Access

Authors

FYB201 is biosimilar to reference ranibizumab in terms of clinical efficacy and ocular and systemic safety in the treatment of patients with nAMD.

Good health and well-being

Published in: Ophthalmology

Volume 129, Issue 1, pp. 54-63

Field-Weighted Citation Impact: 7.87